Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'' by Pethoe-Schramm et al

Ann Rheum Dis. 2022 Aug;81(8):e137. doi: 10.1136/annrheumdis-2020-218403. Epub 2020 Jul 31.
No abstract available

Keywords: antirheumatic agents; arthritis, rheumatoid; inflammation.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / chemically induced
  • Arthritis, Rheumatoid* / drug therapy
  • C-Reactive Protein
  • Humans
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • C-Reactive Protein
  • tocilizumab